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Pharmacovigilance Forum

Benzocaine-Induced Methemoglobinemia:
A Case Report
Keith T. veltri, PharmD; and ellen rudnick, mS, BPharm

INTRODUCTION

Local anesthetics are classified by
their chemical structures, with the two
major categories being esters and amides
(Table 1). The agent of choice depends
on the method of administration, the
length of time for which the affected areas
require local anesthesia, and potential
adverse effects.
Esters include benzocaine (Cepacol,
Reckitt Benckiser; Dermoplast, Prestige
Brands Holdings; Chloraseptic, Prestige
Brands Holdings; HurriCaine, Beutlich
Pharmaceuticals; Lanacane, Reckitt
Benckiser; Orabase, Colgate-Palmolive
Company; Orajel, Church & Dwight; and
Zilactin, Blairex Laboratories); chloroprocaine (Nesacaine, APP Pharmaceuticals);
procaine (Novocaine, Colgate-Palmolive
Company); and tetracaine.1
Amides include bupivacaine (Marcaine, Hospira; Sensorcaine, AstraZeneca); dibucaine (Nupercainal, Nucere
Pharma); levobupivacaine (Chirocaine,
Purdue Pharma); lidocaine (Dilocaine,
Shire; Solarcaine, Bayer; Lidoderm,
Endo Pharmaceuticals; and Xylocaine,
Fresenius Kabi USA); mepivacaine (Carbocaine, Cooke-Waite; Isocaine, Novocol Pharmaceutical; Polocaine, Novocol
Pharmaceutical); prilocaine (Citanest,
Dentsply Pharmaceutical); and ropivacaine (Naropin, Fresenius Kabi).1
Some combination products contain
both amides and esters; the most comDr. Veltri is Associate Professor at Touro
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Welcome to the Pharmacovigilance Forum,
where we report on interesting adverse drug
reactions (ADRs), including drug-induced disease.
ADRs are a leading cause of morbidity and mortality. The Institute of Medicine has estimated that
44,000 to 98,000 deaths
occur annually from medical errors, with 7,000 due
to ADRs. Studies suggest
that 6.7% of hospitalized
patients have a serious
ADR; about 0.5% die as a
consequence. ADRs are a
signiﬁcant, preventable public health problem
that we can help mitigate through education.
Drug approvals in the U.S. continue to grow.
In 2015, the Food and Drug Administration (FDA)
approved 45 novel drugs—up from an average
of about 28 per year from 2006 through 2014.
This is a signiﬁcant increase, especially since

monly used of these agents include lidocaine/prilocaine (Emla, Akorn, Inc.) and
benzocaine/tetracaine/butamben (Cetacaine, Cetylite Industries).1
Amides have largely replaced the
esters because they produce fewer
adverse effects and generally have a longer duration of action.1
Pramoxine (Analpram, Sebela Pharma-

Table 1 General Anesthetic Agents1
Esters
•
•
•
•

Benzocaine
Chloroprocaine
Procaine
Tetracaine

Amides
•
•
•
•
•
•
•

Bupivacaine
Dibucaine
Levobupivacaine
Lidocaine
Mepivacaine
Prilocaine
Ropivacaine

Miscellaneous
• Pramoxine

many of these approvals involved complex biologic agents. Yet all pharmaceuticals carry a risk
of ADRs, whether they are new and improved,
generic agents, older brand products, complex
biologics, or biosimilars. Publishing ADR cases is
a great way to educate others about little-known
reactions, unique patient management of a
reaction, or interesting presentations of known
reactions to a drug or drug class.
Each Pharmacovigilance Forum will discuss
noteworthy topics related to ADRs in the clinical realm. Every medication has the potential to
cause disease, but clinicians are often slow to
recognize drug therapy as an etiological factor.
I encourage anyone with a potentially interesting case to contact me, to publish ADRs here
or elsewhere, and to report ADRs to the FDA
MedWatch program.
—Michele B. Kaufman

ceuticals; Itch-X, B. F. Ascher & Company;
Pramegel, Pharmaderm; Pramosone,
Sebela Pharmaceuticals; Prax, Ferndale
Laboratories; and Tronolane, Abbott
Laboratories) is a local anesthetic that
does not belong to either the amide or
ester class.1
Local anesthesia can be achieved by
various methods, including topical administration, infiltration, field block, nerve
block, and intravenous regional injection.
The method by which a local anesthetic
is administered aids its effectiveness
by delivering the agent directly to the
area that is causing or will cause pain.
This decreases systemic absorption and
related toxic effects. Systemic absorption
could produce toxic effects on both the
cardiovascular and nervous systems.1
Recently, topical anesthetics have been
reported to cause methemoglobinemia,
an elevated fraction of methemoglobin (an
unstable type of hemoglobin within erythrocytes). The popularity of benzocaine as
Disclosure: The authors report no commercial or financial relationships in regard to this
article.
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a topical anesthetic has diminished as a
result of increasing concerns regarding
its potential to induce this hematological
disorder. Numerous case reports have
been published.2–17 As of 2009, a review
of 242 published cases implicated benzocaine in 66% of methemoglobinemia
related to local anesthesia, while lidocaine
accounted for only about 5% of cases.13

PATHOPHYSIOLOGY

Hemoglobin is composed of four
heme groups: deoxyhemoglobin, oxyhemoglobin, carboxyhemoglobin, and
methemoglobin. Each group contains
an iron atom capable of binding oxygen.
This binding, however, can occur only
if the iron is in the reduced state (Fe+2).
The removal of an electron from reduced
iron—oxidizing it from Fe+2 to Fe+3—produces methemoglobin. In addition, the
production of a ferric (Fe+3) heme group
interferes with oxygen unloading by the
other ferrous (Fe+2) heme groups on the
hemoglobin molecule. Red blood cells are
continuously under stress by oxidative
processes and undergo numerous structural changes that result in the formation
of methemoglobin. The development of
methemoglobin is regulated by various
enzymatic processes, which include the
major pathway nicotinamide adenine
dinucleotide methemoglobin reductase
and the minor pathway nicotinamide adenine dinucleotide phosphate (NADPH)
methemoglobin reductase.2,4,7,9 A small
amount of methemoglobin is reduced via
nonenzymatic pathways, such as by ascorbic acid, reduced glutathione, riboflavin,
and cysteine.5 During these major and
minor processes, iron is in the ferrous
form (Fe+2) and combines with oxygen for
transportation to the tissues.2,4,7–9
Because methemoglobin prevents oxygen transport to cells, patients presenting with methemoglobinemia become
cyanotic despite an adequate respiratory status. Increased oxygenation has
no effect on either the cyanotic state or
oxygen saturation. Pulse oximetry will
most likely be inaccurate, and readings
will be inconsistent with the patient’s
increasing cyanosis.5 Oxygen saturation
measured by pulse oximetry is typically
in the range of 80% to 85% regardless of
the severity of methemoglobinemia.4 Routine analysis of arterial blood gas is used
to determine the partial pressure of oxygen (PO2), which is then used to calculate

oxygen saturation in the blood. However,
the measurement of PO2 is not affected by
the presence of methemoglobin, and as a
result, pulse oximetry readings that are
inconsistent with oxygen saturation are
suggestive of methemoglobin.4,5
A pulse oximeter is a noninvasive
device attached to the finger, earlobe,
or nose that emits two separate wavelengths of light, red (660 nm) and infrared
(940 nm). A co-oximeter is used to measure the absorbance of oxyhemoglobin and
deoxyhemoglobin circulating throughout
the capillaries. It reflects the amount of
oxygen in the blood, expressed as a percentage, measuring light absorbance at
four different wavelengths, correlating to
the absorption characteristics off all four
heme groups.18 Carboxyhemoglobin has
an almost identical absorption spectrum
(660 nm) to that of oxyhemoglobin.18
Methemoglobin absorbs light at both
wavelengths (660 nm and 940 nm) that
standard oximeters emit.18 Therefore, a
definitive diagnosis should be confirmed
by co-oximetry in patients who present
with cyanosis of an uncertain cause.
A “filter paper test” provides a rapid
bedside method for diagnosing methemoglobin. In patients with this disorder,
arterial blood, when drawn and placed on
the filter paper, is often chocolate brown
or black and does not change color when
exposed to oxygen.4,5,9
The clinical manifestations of methemoglobinemia directly correlate with the level
of measured methemoglobin. Symptoms
can be worse in those at age extremes
(e.g., very young or very old) or with multiple comorbidities. Elderly and pediatric
patients, as well as hypoxic patients, are
more prone to the formation of methemoglobin. Neonates express low levels of functional NADPH methemoglobin reductase,
and this enzyme becomes less efficient
in the elderly.17 A normal methemoglobin
level is less than 1% to 3% of the fraction
of hemoglobin in healthy individuals.
When the methemoglobin level indicated
through arterial co-oximetry is 15% to 20%,
patients are usually cyanotic, but they may
be asymptomatic. When methemoglobin
levels reach 20% to 50%, the patient may
experience headache and lightheadedness,
weakness, chest discomfort, palpitations,
and dyspnea. Death can occur when methemoglobin levels exceed 70%.2,5–7,10
Methemoglobinemia usually results
from exposure to an external oxidizing

agent that compromises the physiological cellular defenses of red blood cells.
The disorder can also be hereditary. It is
associated with the production of abnormal hemoglobin, which usually presents
as cyanosis at birth or as a secondary
feature of NADH reductase deficiency.5,12
Exogenous agents that pose a risk for
methemoglobinemia are listed in Table 2.

Table 2 Selected Agents Associated
With Methemoglobinemia5–7, 9, 11
High Risk
•
•
•
•
•
•

Benzocaine
Chloroquine
Ciprofloxacin
Dapsone
Flutamide
Isosorbide
dinitrate
• Metoclopramide
• Naphthalene
• Nitrofurantoin

•
•
•
•
•
•
•
•
•
•

Nitroglycerin
Nitric oxide
Phenazopyridine
Phenelzine
Phenobarbital
Prilocaine
Primaquine
Quinine sulfate
Sulfonamides
Trimethoprim

•
•
•
•

Fentanyl
Lidocaine
Mepivacaine
Nitrous oxide

•
•
•
•

Phenothiazines
Propofol
Succinylcholine
Thiopental

Moderate Risk
•
•
•
•

Acetaminophen
Aspirin
Bupivacaine
Etidocaine

Low Risk
• Benzodiazepines
• Ibuprofen
• Inhalational
anesthetics
• Meperidine

PRINCIPLES OF TREATMENT
AND REPLACEMENT

The topical anesthetics benzocaine
20% (HurriCaine spray) and lidocaine
are readily available in most emergency
departments and are commonly used
to anesthetize a patient’s airway before
elective endotracheal intubations or endoscopic procedures.14 Both agents have
been reported to cause methemoglobinemia. A recent review of the literature
indicated that methemoglobinemia was
reported more frequently with spray benzocaine used during dental or endoscopic
procedures (such as for transesophageal
echocardiography).14 The potentially fatal
effects of benzocaine may be due to a
toxic metabolite, an N-hydroxy derivative
that has an aniline group incorporated
into its structure.6,14 This compound has
oxidizing properties.
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Case Report
if the methemoglobin level remained above
The following report describes a patient
20%. The patient ultimately received two
with benzocaine-induced methemoglobindoses of 70 mg in two hours before there
emia who was seen at our hospital.
was an initial decline in the methemogloA 46-year-old woman with a medical hisbin level (Figure 1). The patient became less
tory of hypertension, anemia, depression,
cyanotic, and her oxygenation improved
and morbid obesity (which persisted after a
(Table 3). Hematology further recommended
gastric bypass in 2003) presented on April 3,
that the medical team continue trending the
2013, for laparoscopic fistula repair and revipatient’s methemoglobin levels over the next
sion of her 2003 gastric bypass. She felt
24 hours. This was advised because of the
potential for a rebound effect, which could
well at discharge, but soon afterward she
experienced chest pain that “felt as though
occur secondary to the presence of the circuan elephant was sitting on her chest.” She
lating oxidant. Repeat methylene blue doses
presented to the emergency department
were not recommended unless the patient’s
on April 12. An upper gastrointestinal series
methemoglobin level exceeded 20%.
and computed tomography revealed free air in
Figure 1 Level of Methemoglobin Before
the upper abdomen and a
and After Methylene Blue Treatment
large extraluminal contrast
50
collection posterior to the
gastric pouch, with free
air bubbles in the upper
40
quadrant. She decompenMethylene blue 1 mg/kg
38.8
sated, and a nasogastric
(NG) tube was temporarily
30
placed. After removal of
the NG tube, benzocaine
20% topical oral spray
20.4
20
(HurriCaine) was ordered,
with nursing instructions
to apply one spray to the
10
back of the throat. The
7.1
order also included instruc2.2
tions to repeat the spray
0
every six hours for pain
0 1 2 3 4 5 6 7 8 9 10 11 12
relief. The following day,
the nurse accidentally left
Hours after methylene blue administration
the HurriCaine spray canister at the patient’s bedside,
DISCUSSION
and the patient subsequently overdosed as
the result of continuous excessive adminNumerous case reports have described
istration of the anesthetic over the next
methemoglobinemia after gastrointestifour days.
nal endoscopy, endotracheal intubation,
bronchoscopic NG tube placement, and
On the morning of April 17, the patient
was found to be cyanotic and “blue.” The
other inpatient procedures that involve
patient stated that she felt short of breath,
prescription topical anesthetics. Howdizzy, and fatigued. She was immediately
ever, many over-the-counter (OTC) topiplaced on 2 L of oxygen via nasal cannula.
cal anesthetic gels, throat lozenges, or
Later that morning, she desaturated to 83%
sprays can cause methemoglobinemia.
and was placed on 100% fraction of inspired
The easy access to OTC benzocaine prodoxygen (Fi02). An arterial blood gas (ABG)
ucts, such as Cepacol anesthetic troches
was ordered “stat.” The ABG showed a
(Reckitt Benckiser) and Sucrets maximethemoglobin level of 38.8%.
mum-strength lozenges (Prestige Brands
At this point, the medical team conHoldings), may lead clinicians to believe
tacted the hematology service regarding
that these products are free from adverse
therapeutic management for this patient.
effects, including methemoglobinemia.
The hematology service recommended
Methemoglobinemia often occurs
immediate treatment with methylene blue
when the doses of benzocaine spray (or
1 mg/kg, with a repeat dose one hour later
other local anesthetic agents) exceed
Methemoglobin level (%)

From November 1997 through March
2002, 132 cases of methemoglobinemia
associated with benzocaine administration were reported to the FDA. In 123
of these cases (93%), the product was
a spray; in two cases, the product was
a benzocaine-containing lozenge; and
in one case, it was a gel.14 These percentages may not accurately represent
actual occurrence rates because cases
were likely underreported. For example,
patients with mild methemoglobinemia
may be asymptomatic or may present
with only mild symptoms, which may
not be recognized as potential cases
of drug-induced methemoglobinemia.
Differences in absorption and metabolism may explain the variability of benzocaine-induced methemoglobinemia in
these individuals.6,14
Mild methemoglobinemia can be
treated with supplemental oxygen to
maximize the oxygen-carrying capacity
of the remaining normal hemoglobin after
removal of the causative agent. These
cases generally do not require specific
treatment.4,5 Symptomatic patients with
methemoglobinemia presenting with
methemoglobin levels exceeding 20% to
30% should receive methylene blue, which
acts as a cofactor for the enzyme NADPH
methemoglobin reductase. Electrons are
transferred from NADPH to methylene
blue, which leads to a reduction of the
heme iron to deoxyhemoglobin.9 Methylene blue should be administered at an
initial intravenous dose of 1 mg/kg to
2 mg/kg over five minutes.4,5,9 If there is
no response, a repeat 1-mg/kg dose may
be administered after 30 to 60 minutes.5,9
The adverse effects of methylene blue
include bluish skin discoloration (which
can complicate the assessment of cyanosis), hemolysis, gastrointestinal distress,
bladder irritation, and rebound methemoglobinemia, particularly with doses
that exceed 7 mg/kg.4,5,9 Methylene blue
should not be administered to patients
with glucose-6-phosphate dehydrogenase
(G6PD) deficiency or with congenital
abnormal hemoglobin or NADH reductase deficiency. Low levels of NADPH are
present in these patients, and as a result,
methylene blue will be ineffective and will
ultimately cause hemolysis. Exchange
transfusions should be considered in
these individuals.4,5,7,9
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7.350–7.450

7.490

7.398

7.434

7.404

PCO2 (mm Hg)

35.0–45.0

31.7

43.1

38.8

46.0

caine spray ordered for “sore throat.” Our
staff has been educated on contacting the
prescriber to recommend an alternative
agent, such as benzocaine troches or lozenges, or phenol 0.5% spray (Chloraseptic,
Prestige Brands Holdings), which can be
administered to both adults and pediatric
patients over the age of 2 years.

PO2 (mm Hg)

80–100

180.0

57.3

71.5

139.0

CONCLUSION

HCO3 (mmol/L)

22.0–28.0

23.9

26.0

25.6

28.1

94–100

96.3

88.2

92.9

97.8

60–90

59.6

69.9

85.7

94.3

Carboxy Hb

< 9.1

0.0

0.4

0.7

1.4

MetHb

< 1.6

38.8

20.4

7.1

2.2

Deoxy Hb (%)

<2

Table 3 Arterial Blood Gases and Co-Oximetry Values
Normal
Values

Time of
Diagnosis

Time after Administration of Methylene Blue
3 hours

5 hours

10 hours

Arterial blood gas
pH

SaO2

Arterial co-oximetry
O2Hb

FiO2 (%)

2.3

9.3

6.5

2.2

4L NC

6L NC

4L NC

80%

Carboxy Hb = carboxyhemoglobin; deoxy Hb = deoxyhemoglobin; FiO2 = fraction of inspired oxygen;
Hb = hemoglobin; HCO3 = plasma bicarbonate; metHb = methemoglobin; NC = nasal canula;
O2Hb = oxyhemoglobin; PCO2 = partial pressure of carbon dioxide; PO2 = partial pressure of oxygen;
SaO2 = arterial saturation of oxygen.

Table 4 Minimizing the Risk of Methemoglobinemia
When Using Topical Anesthetics21
• Affix labels to topical anesthetic spray bottles warning staff of the danger of excessive
patient use.
• Identify risk factors while obtaining the patient’s medical history.
• Document the amount of drug administered, including measuring and recording the
number of sprays applied. The use of a reference chart with maximum recommended
doses of anesthetics may be helpful.
• Supplemental oxygen and methylene blue should be kept handy whenever topical
anesthetics are used.
• Use delivery devices that provide more precision in drug administration, such as atomizers
(many are available).
• Stock only one topical anesthetic product to reduce dosing confusion. Lidocaine may be
safer than benzocaine.
the manufacturers’ recommendations.
Clinicians have long pointed out that
ambiguous package instructions for
use of the spray canisters of benzocaine
products can be easily misinterpreted
and can lead to potential overdoses. Package instructions commonly suggest that
the user should “activate the spray with
the forefinger for approximately one second. Maximum anesthesia is produced in
one minute.” 19 This direction could easily
be misinterpreted to mean that a continuous spray of up to one minute is permitted
and even desirable for maximum anesthesia.19 OTC benzocaine formulations may
contain up to 20% benzocaine, and sprays
containing benzocaine deliver 45 mg to

60 mg of the anesthetic in one second.
Adverse events related to topical anesthetics usually involve the use of multiple
sprays or of sprays lasting longer than the
recommended duration.3,11,20 Table 4 lists
several strategies to reduce the risk of
methemoglobinemia when using topical
anesthetics.21
After discussing the potential for methemoglobinemia in patients treated with
topical anesthetics, our pharmacy department decided to remove the HurriCaine
spray canister from the formulary and
replace it with unit-dose nonspray benzocaine (HurriCaine One), thus making it
easier to control the amount of drug being
administered. We continue to see benzo-

Methemoglobinemia is a persistent
and significant clinical condition that can
result from the use of topical anesthetics,
among other causes. Although it is treatable, its detection has been complicated by
a general lack of awareness in the medical
community and by the limited availability
of standard co-oximetry for an accurate
diagnosis in the inpatient setting. Clinicians should be on the alert for this potentially serious disorder if patients show an
inconsistency between the oxygen saturation of arterial blood and the saturation
calculated from partial pressure of oxygen. In addition, methylene blue should be
readily available in facilities where topical
anesthetics are administered.

REPORTING ADVERSE
DRUG REACTIONS

All ADRs should be reported to MedWatch at 1-888-INFO-FDA, 1-888-4636332, or online. The FDA 3500 Voluntary Adverse Event Report Form can be
accessed easily online for reporting ADRs
at www.fda.gov/Safety/Medwatch/HowToReport/ucm085568.htm.
The FDA is interested in serious reports
that include any of the following patient
outcomes: death; life-threatening condition; initial hospitalization; prolonged hospitalization; disability or permanent damage; congenital anomalies or birth defects;
and other serious conditions for which
medical or surgical intervention is needed
to prevent one of the aforementioned outcomes. The FDA is also interested in any
unlabeled ADRs for new drugs.
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